Wanted: Inclusive Guidelines for Research Involving Pregnant Women

Journal of Obstetrics and Gynaecology Canada

Volumn 32, Issue 5, 2010, Pages 473-476

  Baylis, Françoise ^a   Kaposy, Chris ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Inclusion in research; Pregnancy; Research ethics; Tri Council Policy Statement

Indexed keywords

CONSULTATION; FEAR; FUNDING; HUMAN; MEDICAL RESEARCH; NOTE; PATIENT COUNSELING; PATIENT SAFETY; PRACTICE GUIDELINE; PREGNANT WOMAN; RESEARCH ETHICS; RISK ASSESSMENT; RISK REDUCTION; WOMEN'S HEALTH; ARTICLE; FEMALE; PATIENT SELECTION; PREGNANCY; RESEARCH SUBJECT;

ETHICS, RESEARCH; FEMALE; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANT WOMEN; RESEARCH SUBJECTS;

EID: 77953429234     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)34502-9     Document Type: Note

References (20)

1. Canadian Institutes of Health Research Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. Tri-council policy statement: ethical conduct for research involving humans 2005, Public Works and Government Services Canada, Ottawa, Available at: Accessed March 8, 2010. http://pre.ethics.gc.ca/policy-politique/tcps-eptc/docs/TCPS%200ctober%202005_E.pdf.
2. Interagency Panel on Research Ethics Revised draft 2nd edition of the Tri-council policy statement: ethical conduct for research involving humans 2009 Dec, Interagency Secretariat on Research Ethics, Ottawa, Available at: Accessed March 8, 2010. http://pre.ethics.gc.ca/pdf/eng/Revised.
3. Interagency Panel on Research Ethics Navigating the ethics of human research. Ottawa: Interagency Secretariat on Research Ethics; 2009. Release for final public comment-revised draft, 2nd edition of the TCPS 2009 Dec 21, Interagency Secretariat on Research Ethics, Ottawa, Accessed March 8, 2010. http://www.pre.ethics.gc.ca/eng/resources-ressources/.
4. Dresser R. Wanted: single, white male for medical research. Hastings Cent Rep 1992, 22:24-29.
5. DeBruin D.A. Justice and the inclusion of women in medical research. Kennedy Inst Ethics J. 1994, 4:117-146.
6. Giacomini M., Baylis F. Excluding women from medical research: reasons and rejoinders. Clinical Researcher 2003, 3(10):11-15.
7. Baylis F. Women and health research: working for change. J Clin Ethics 1996, 7:229-242.
8. Baylis F., Downie J., Sherwin S. Reframing research involving humans. The politics of women's health: exploring agency and autonomy 1998, 234-259. Temple University Press, Philadelphia. S. Sherwin, F. Baylis, M. Bell, M. De Koninck, J. Downie, A. Lippman (Eds.).
9. Baylis F., Downie J., Sherwin S. Women and health research: from theory, to practice, to policy. Embodying bioethics: recent feminist advances 1999, 253-268. Rowman and Littlefield, New York. A. Donchin, L.M. Purdy (Eds.).
10. Lippman A. The inclusion of women in clinical trials: are we asking the right questions? 2006 March, Women and Health Protection, Toronto, Accessed March 8, 2010. http://www.whp-apsf.ca/pdf/clinicalTrialsEN.pdf.
11. National Institutes of Health. Monitoring adherence to the NIH policy on the inclusion of women and minorities as subjects in clinical research. Comprehensive report: tracking human subjects research as reported in fiscal year 2006 and fiscal year 2007. Washington: Department of Health and Human Services; 2008 Fall. Available at:. http://orwh.od.nih.gov/inclusion/FinalAnnualReport2007.pdf.
12. Shrim A., Berger H., Kingdom J., Hamoudi A., Shah P.S., Koren G. Prolonged exposure to angiotensin-converting enzyme inhibitors during pregnancy: fetal toxicity could be reversible. Motherisk Update. Can Fam Physician 2005, 51:1335-1337.
13. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy-United States, Canada and Israel, 1987-1995. MMWR Morb Mortal Wkly Rep 1997, 46:240-242. Centres for Disease Control and Prevention.
14. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., Dudley J.A., Dyer S., Gideon P.S., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006, 354:2443-2451.
15. Baylis F. An unnecessary risk. The Mark News 2010 Jan 15, Public Works and Government Services Canada, Ottawa, Available at: Accessed March 8, 2010. http://themarknews.com/articles/830-an-unnecessary-risk.
16. Martin J.A., Hamilton B.E., Sutton P.D., Ventura S.J., Menacker F., Kirmeyer S., Matthews T.J., et al. Births: final data for 2006. National Vital Statistics Reports. Hastings Cent Rep 2009, 57(7):1-104. Available at: Accessed March 8, 2010. http://www.cdc.gov/nchs/data/nvsr/.
17. Lyerly A.D., Little M.O., Faden R. The second wave: toward responsible inclusion of pregnant women in research. Int J Fem Approaches Bioeth 2008, 1(2):5-22.
18. National Institutes of Health ClinicalTrials.gov. Washington, 2009. Novartis H1N1 vaccine in pregnant women 2010 Jan 7, Available at. Accessed March 8, 2010. http://:%20http://clinicaltrials.gov/ct2/show/NCT00992719.
19. National Institute of Child Health and Human Development Obstetric-fetal pharmacology research units; 2003. Request for applications for obstetric-fetal pharmacology research units (HD-03-017) 2003 July 29, Available at: Accessed March 8, 2010. http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-03-017.html.
20. Health Canada Prescription drugs labelled for use in pregnancy: the need for a Canadian regulatory framework 2008 Aug 13, Available at: Accessed March 8, 2010. http://26448.vws.magma.ca/dhp-mps/homologation-licensing/docs/issues-enjeux/issues-enjeux14-eng.php.